IL153497A0 - Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - Google Patents

Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Info

Publication number
IL153497A0
IL153497A0 IL15349701A IL15349701A IL153497A0 IL 153497 A0 IL153497 A0 IL 153497A0 IL 15349701 A IL15349701 A IL 15349701A IL 15349701 A IL15349701 A IL 15349701A IL 153497 A0 IL153497 A0 IL 153497A0
Authority
IL
Israel
Prior art keywords
composition
dosage forms
therapeutic agents
controlled release
forms including
Prior art date
Application number
IL15349701A
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL153497A0 publication Critical patent/IL153497A0/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
IL15349701A 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition IL153497A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US21711000P 2000-07-10 2000-07-10
US22321200P 2000-08-04 2000-08-04
PCT/US2001/020134 WO2002000213A1 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Publications (1)

Publication Number Publication Date
IL153497A0 true IL153497A0 (en) 2003-07-06

Family

ID=27395915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15349701A IL153497A0 (en) 2000-06-23 2001-06-22 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Country Status (11)

Country Link
EP (1) EP1305021A4 (en)
JP (1) JP2004501190A (en)
KR (1) KR20030013460A (en)
AU (2) AU6872201A (en)
CA (1) CA2412490A1 (en)
CZ (1) CZ2003199A3 (en)
EA (1) EA200300046A1 (en)
HU (1) HUP0301465A3 (en)
IL (1) IL153497A0 (en)
MX (1) MXPA02012793A (en)
WO (1) WO2002000213A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
NZ531461A (en) * 2001-08-16 2008-03-28 Oregon State Expandable gastric retention device
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
WO2004091601A1 (en) * 2003-04-17 2004-10-28 Jallal Messadek Floating oral formulations for controlled release of betaine
MXPA06004327A (en) * 2003-10-20 2007-01-26 Teva Pharma Composition and dosage form for sustained effect of levodopa.
JP2005132803A (en) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd Solid pharmaceutical preparation staying in stomach
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
FR2874325B1 (en) * 2004-08-19 2006-10-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION IN THE FORM OF A GASTRIC RESISTANCE COMPRESSOR CONTAINING ALFUZOSIN
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
CN101180073A (en) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 Insulins combinations
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
ZA200810834B (en) * 2006-05-31 2010-03-31 Solvay Pharm Gmbh Long term 24 hour intestinal administration of levodopa/carbidopa
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008030830A2 (en) * 2006-09-08 2008-03-13 Drugtech Corporation Sustained-release composition and method of use thereof
EP2066303B1 (en) * 2006-09-26 2016-05-04 Plensat, LLC System for treatment of eating disorders
JPWO2008087882A1 (en) 2007-01-15 2010-05-06 キッセイ薬品工業株式会社 Stomach retention type levodopa sustained release formulation
KR20080076382A (en) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 Controlled-release preparation containing cilostazol and process for the preparation thereof
DE102007026037A1 (en) * 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentive system with alginate body
US20090028941A1 (en) * 2007-07-27 2009-01-29 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN102076215A (en) 2008-06-30 2011-05-25 托卡根公司 Formulations of 5-fluorocytosine and uses thereof
MX340249B (en) * 2008-08-15 2016-07-01 Depomed Inc Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders.
CN102238946B (en) * 2008-11-07 2014-11-26 株式会社三养生物制药 Pharmaceutical composition for the controlled release of methylphenidate
EP2661262B1 (en) * 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
CN103385871B (en) * 2012-05-07 2017-06-23 新疆医科大学 Benserazide micro-capsule floating tablet
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
JP6204141B2 (en) * 2013-04-22 2017-09-27 テイカ製薬株式会社 Oral rapidly disintegrating composition for solid preparation
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
PL3054929T3 (en) 2013-10-07 2021-05-31 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
BR112016012615B1 (en) * 2013-12-05 2023-02-07 Epitomee Medical Ltd SYSTEMS, AND KIT
MX2017011005A (en) * 2015-02-27 2018-01-16 Cingulate Therapeutics LLC Tripulse release stimulant formulations.
JP6823539B2 (en) * 2017-05-26 2021-02-03 株式会社ファンケル Gastric retention tablets
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN110996922A (en) 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 Gastric retentive dosage forms for sustained drug delivery
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
JP7034343B2 (en) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー Self-regulating permeable gastric retention drug delivery system
JP7044649B2 (en) * 2018-06-28 2022-03-30 株式会社ファンケル Intragastric floating tablets
EP3968980A1 (en) * 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US20220409490A1 (en) * 2020-03-02 2022-12-29 Craft Health Pte Ltd Method of manufacturing oral dosage forms for extended drug release
US11571402B2 (en) * 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1282650B1 (en) * 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
JP2001510788A (en) * 1997-07-23 2001-08-07 ペリオ プロダクツ リミテッド Tannic acid polymer compositions for pharmaceutically controlled release of pharmaceutical agents into the oral cavity

Also Published As

Publication number Publication date
WO2002000213A1 (en) 2002-01-03
AU2001268722B8 (en) 2005-09-29
AU2001268722B2 (en) 2005-08-11
HUP0301465A2 (en) 2004-05-28
AU6872201A (en) 2002-01-08
CZ2003199A3 (en) 2003-12-17
EA200300046A1 (en) 2003-10-30
EP1305021A4 (en) 2009-09-23
MXPA02012793A (en) 2004-07-30
KR20030013460A (en) 2003-02-14
JP2004501190A (en) 2004-01-15
CA2412490A1 (en) 2002-01-03
HUP0301465A3 (en) 2006-07-28
EP1305021A1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
IL153497A0 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU8405201A (en) Contraception process and administration form for the same
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
MXPA03003895A (en) Controlled release hydrocodone formulations.
HUP0301242A3 (en) Controlled release drug dosage form
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
GB0002386D0 (en) Therapeutic composition
FI20000780A (en) Oral dosage form for controlled release of the drug
MXPA03004303A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain.
EP1501352A4 (en) Methods and compositions for controlled release of drugs
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
HUP0102159A3 (en) Pharmaceutical composition for the treatment of rumen acidosis
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
GB0030067D0 (en) Therapeutic agent
EP1357898A4 (en) Improved controlled release oral dosage form
HK1046848A1 (en) Specific therapeutic composition for treating aids
HK1055954A1 (en) Crystalline therapeutic agent.
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis